| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | fluticasone furoate/umeclidinium/vilanterol (Elebrato® Ellipta®) |
| Formulation | inhalation powder |
| Reference number | 3978 |
| Indication | Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease who are not adequately treated by a combination of an inhaled long-acting β2-agonist and long-acting muscarinic receptor antagonist (for effects on symptom control and prevention of exacerbations) |
| Company | Glenmark Pharmaceuticals Ltd |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 09/05/2019 |